Metabolic Dysfunction-Associated Steatohepatitis in the Middle East: Clinical Challenges and Strategies to Bridge the Gap.

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive subtype, metabolic dysfunction-associated steatohepatitis (MASH), are growing global health concerns. In the Middle East, rising rates of obesity and diabetes contribute to an increasing burden of MASLD and MASH. However, countries across the region vary in care models, health care infrastructure, and workforce capacity. Gaps remain in health policy, research infrastructure, and participation in global studies. This review outlines the current landscape of MASH in the Middle East and discusses strategies to strengthen diagnosis, management, and regionally relevant evidence generation.